Report cover image

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

Publisher Kalorama Information
Published Jul 27, 2016
Length 340 Pages
SKU # KLI15068137

Description

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 analyzes the leading concerns in the pharmaceutical industry, including the late-term pipeline of major competitors. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report includes late stage product pipeline; late stage product pipeline by therapeutic area, comparing 2009, 2011, 2013 and 2015; total company revenue and total R&D spending, 2011-2015; leading pharmaceutical products, 2015 sales; break-up of sales by region, 2015; pharmaceutical segment sales, 2011 through 2015 and forecasted 2025; and pharmaceutical business performance, 2011-2015 and forecasted 2025. Merck, Novartis, Pfizer, Roche, and Sanofi are among the top manufacturers examined.

Table of Contents

340 Pages
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • FUTURE MARKET OPPORTUNITY
    • LEADING COMPANIES
    • CONCLUSIONS
    • GLOBAL PHARMACEUTICAL MARKET
    • TOP 25 PHARMACEUTICAL COMPANIES: AN OVERVIEW
    • GLOBAL HEALTHCARE SPENDING
    • AGING POPULATION AND IMPACT ON PHARMACEUTICAL MARKETS
    • PHARMACEUTICAL RESEARCH & DEVELOPMENT CHALLENGE
    • THE DRUG APPROVAL PROCESS
    • EXPANDED OPTIONS IN TREATING DISEASES
    • BIOTECHNOLOGY DRUG DEVELOPMENT
    • ORPHAN DRUGS
    • FAST TRACK DRUG STATUS
    • OTHER ACCELERATED METHODS FOR DRUG APPROVAL
    • PHARMACEUTICAL REGULATORY EXCLUSIVITY
    • THE ROLE OF CONTRACT RESEARCH ORGANIZATIONS
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • FINANCIAL PERFORMANCE AND INVESTMENTS
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
    • GROWTH STRATEGY
    • COMPANY OVERVIEW
    • MARKET TRENDS AND VALUES BY THERAPEUTIC AREA
    • EVALUATING CHANGES IN 2015 MARKET VALUE
    • COMPANY ANALYSIS
    • MARKET FORECAST
    • FUTURE COMPANY OUTLOOK

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us